Thymosin Alpha-1 for immune support
Thymosin Alpha-1 is the most-studied immune peptide. It tunes the adaptive immune system, run as a twice-weekly course.
6–12 weeks + 4–8-week washout
Why this protocol
Thymosin Alpha-1 (Tα1) is a fragment of the thymic protein prothymosin alpha. It modulates the adaptive immune system, shifting T-cell activity and dampening over-reactive inflammation. Its twice-weekly, 1.6 mg dose is the schedule used in human trials for hepatitis B and as a vaccine adjuvant.
It is a mono protocol because the evidence is built around the single agent on a steady twice-weekly schedule. Its most rigorous critical-illness trial, for sepsis, found no benefit, so this is immune modulation rather than a treatment for a specific illness.
The regimen
Thymosin Alpha-1
Immune modulation- Dose
- 1.6 mg
- Schedule
- Twice weekly · subcutaneous
- Timing
- Consistent days each week (no circadian data)
Reconstitution calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
32 units
Draw this many units on a U-100 syringe
Each unit holds 50 mcg
- Volume per dose
- 0.32 mL
- Doses per vial
- 6
- Concentration
- 5 mg/mL
One vial lasts
- Daily
- 6 days
- Every other day
- 12 days
- 5×/week
- 8 days
- Large draw (32 units). That's normal for mg doses. To check it, multiply the units by what each unit holds. You should get your dose.
Research use only. Not for human consumption. Outputs are reference values based on research literature. Verify all measurements independently.
Cycle & schedule
- Cycle (6–12 weeks)Tα1 1.6 mg subcutaneously twice weekly for 6–12 weeks, then assess.
- Washout (4–8 weeks)A 4–8-week break before repeating. Tα1's serum half-life is short (under 3 hours), so it does not accumulate between doses.
Studies behind this protocol
This protocol composes the cited evidence on each peptide's page. See the full bibliography on: Thymosin Alpha-1.
Research use only · Not medical advice · Updated 2026-09-24